Study summary
Ponsegromab helped people with cancer weight loss regain weight
What was tested
Ponsegromab, an antibody that blocks GDF-15, a hormone that drives appetite loss and wasting, against placebo in people with cancer cachexia, about a third with pancreatic cancer.
What they found
- People on ponsegromab gained significantly more weight at 12 weeks than on placebo.
- Appetite and activity also improved.
- Side effects were no more common than with placebo.
What it means
Wasting affects most people with pancreatic cancer. A 982-person phase 3 is now testing it.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.